PARP1 and prostate carcinoma: The past decade has seen several therapeutic breakthroughs for prostate cancer, including the approval of two PARP inhibitors—rucaparib and olaparib—for mCRPC patients harboring germline or somatic aberrations in DDR genes such as BRCA1 and BRCA2 [4].